about
Adjuvants for peptide-based cancer vaccinesBiodegradable polymeric microsphere-based vaccines and their applications in infectious diseasesMultivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization enhancing the anti-tumor efficacy of doxorubicin nanoliposomes.Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapyDevelopment and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.Nanocarrier-based immunotherapy in cancer management and research.Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.Porous silicon advances in drug delivery and immunotherapy.Nanoparticle-based vaccine delivery for cancer immunotherapy.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Immunomodulatory effects of coated gold nanoparticles in LPS-stimulated in vitro and in vivo murine model systems.Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-TherapyStimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres.Strategy for the hemocompatibility testing of microparticles.Comprehensive Mechanism Analysis of Mesoporous-Silica-Nanoparticle-Induced Cancer Immunotherapy.Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy.
P2860
Q28072236-1CFC56FE-E9F4-4F3D-8810-F38FB84FD2F3Q28087409-EB914113-06B1-4C9D-8153-D8E1AD33B374Q35149189-29CC4F1C-D112-4E87-9917-E2BF1E57335EQ36110892-E332D57E-C9DF-46E8-B052-D8BFFF19C44AQ36642860-F56F3D7E-2AA6-4241-8189-C7241E98DFB6Q37031671-A211BA7D-9576-4C40-BC92-47F4077A5ED8Q37167802-D512A06F-AA30-4E90-8156-5934A417300DQ37227659-69CB2F4D-D8BB-4E36-937C-0E89347FDAF6Q37279161-5CCA1269-F21C-4A93-BC1E-27B07CC5FE5DQ38296086-F355B11D-995E-4326-8172-5619A9F7B82CQ38912004-BDE1DEC8-2B6B-4B06-9E03-E9B5BA755737Q41139823-C2918E48-2A83-4026-88DE-2046D6067815Q42110467-724CC394-F9D8-40BC-B344-C996B4531EACQ42199258-55B7D0A1-124E-4DAE-8398-7071F8FA631DQ48128797-E11826AC-50E1-46B4-ACD3-5EE0C0A80072Q48923498-7C54290F-C081-4257-94D2-6ED77D36F7A2Q50661762-FC0AFD6C-C907-48E4-95EA-1DAB2A0DA3F3Q55163909-128D59AA-195C-47C4-BA0A-3D87B65C39DE
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Particle platforms for cancer immunotherapy.
@en
type
label
Particle platforms for cancer immunotherapy.
@en
prefLabel
Particle platforms for cancer immunotherapy.
@en
P2860
P921
P356
P1476
Particle platforms for cancer immunotherapy.
@en
P2093
Rita Elena Serda
P2860
P304
P356
10.2147/IJN.S31756
P407
P577
2013-04-29T00:00:00Z